Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.

Cheng JP, Leary JB, Sembhi A, Edwards CM, Bondi CO, Kline AE.

Brain Res. 2016 Jun 1;1640(Pt A):5-14. doi: 10.1016/j.brainres.2015.11.026. Epub 2015 Nov 21. Review.

2.

Selective 5-HT(1A)-R-agonist repinotan prevents remifentanil-induced ventilatory depression and prolongs antinociception.

Guenther U, Theuerkauf NU, Huse D, Boettcher MF, Wensing G, Putensen C, Hoeft A.

Anesthesiology. 2012 Jan;116(1):56-64. doi: 10.1097/ALN.0b013e31823d08fa.

PMID:
22082683
3.

Repinotan, a selective 5-HT1A-R-agonist, antagonizes morphine-induced ventilatory depression in anesthetized rats.

Guenther U, Wrigge H, Theuerkauf N, Boettcher MF, Wensing G, Zinserling J, Putensen C, Hoeft A.

Anesth Analg. 2010 Oct;111(4):901-7. doi: 10.1213/ANE.0b013e3181eac011. Epub 2010 Aug 27.

PMID:
20802053
4.

A randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, tolerability, and pharmacokinetic/pharmacodynamic effects of a targeted exposure of intravenous repinotan in patients with acute ischemic stroke: modified Randomized Exposure Controlled Trial (mRECT).

Teal P, Davis S, Hacke W, Kaste M, Lyden PD; Modified Randomized Exposure Controlled Trial Study Investigators, Fierus M; Bayer HealthCare AG.

Stroke. 2009 Nov;40(11):3518-25. doi: 10.1161/STROKEAHA.109.551382. Epub 2009 Sep 10.

PMID:
19745176
5.

Effect of gender and age on the pharmacokinetics of repinotan.

Heinig R, Sundaresan P, Shah A, Boettcher M.

Clin Drug Investig. 2005;25(2):125-34.

PMID:
17523762
6.

Pharmacokinetics of escalating doses of intravenous repinotan in healthy male volunteers.

Heinig R, Böttcher MF.

Clin Drug Investig. 2005;25(2):115-23.

PMID:
17523761
7.

Other neuroprotective therapies on trial in acute stroke.

Ferro JM, Dávalos A.

Cerebrovasc Dis. 2006;21 Suppl 2:127-30. Epub 2006 May 2.

PMID:
16651823
8.
9.

Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach.

Tanigawa T, Heinig R, Kuroki Y, Higuchi S.

Drug Metab Pharmacokinet. 2006 Feb;21(1):61-9.

10.

5-HT1A receptor agonist-mediated protection from MPTP toxicity in mouse and macaque models of Parkinson's disease.

Bezard E, Gerlach I, Moratalla R, Gross CE, Jork R.

Neurobiol Dis. 2006 Jul;23(1):77-86. Epub 2006 Mar 20.

PMID:
16545572
11.

5-HT1A and 5-HT1B receptor agonists and aggression: a pharmacological challenge of the serotonin deficiency hypothesis.

de Boer SF, Koolhaas JM.

Eur J Pharmacol. 2005 Dec 5;526(1-3):125-39. Epub 2005 Nov 28. Review.

PMID:
16310183
12.

Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action.

Díaz-Mataix L, Scorza MC, Bortolozzi A, Toth M, Celada P, Artigas F.

J Neurosci. 2005 Nov 23;25(47):10831-43.

13.

Activation of pyramidal cells in rat medial prefrontal cortex projecting to ventral tegmental area by a 5-HT1A receptor agonist.

Díaz-Mataix L, Artigas F, Celada P.

Eur Neuropsychopharmacol. 2006 May;16(4):288-96. Epub 2005 Nov 14.

PMID:
16290106
14.

Pharmacokinetics of repinotan in healthy and brain injured animals.

Schwarz T, Beckermann B, Buehner K, Mauler F, Schuhmacher J, Seidel D, Steinke W, Weinz C, Zimmerd D.

Biopharm Drug Dispos. 2005 Sep;26(6):259-68.

PMID:
15966026
15.

Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke.

Lutsep HL.

Curr Drug Targets CNS Neurol Disord. 2005 Apr;4(2):119-20. Review.

PMID:
15857296
16.

The BRAINS study: safety, tolerability, and dose-finding of repinotan in acute stroke.

Teal P, Silver FL, Simard D.

Can J Neurol Sci. 2005 Feb;32(1):61-7.

PMID:
15825548
17.

Pupil reaction: a valid sensitive clinical biomarker for 5-HT compounds.

Boettcher M, Heinig R, Wensing G, Kuhlmann J.

Basic Clin Pharmacol Toxicol. 2005 Mar;96(3):246. No abstract available.

18.
19.

Gateways to clinical trials.

Bayés M, Rabasseda X, Prous JR.

Methods Find Exp Clin Pharmacol. 2004 Dec;26(10):801-27.

PMID:
15672123
20.

Gateways to clinical trials.

Bayés M, Rabasseda X, Prous JR.

Methods Find Exp Clin Pharmacol. 2004 Apr;26(3):211-44.

PMID:
15148527

Supplemental Content

Loading ...
Support Center